Literature DB >> 21856683

Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.

David Scheie1, Torstein R Meling, Milada Cvancarova, Kari Skullerud, Sverre Mørk, Knut Lote, Tor J Eide, Eirik Helseth, Klaus Beiske.   

Abstract

We analyzed the relationships among clinical variables, histology, 1p/19q status, and outcome in 95 patients with oligodendroglial tumors. The study enrolled adult patients who underwent first-time surgery for a supratentorial oligodendroglial tumor at Oslo University Hospital, Rikshospitalet. Tumors were: 27 oligodendrogliomas, WHO grade II; 32 oligoastrocytomas, WHO grade II; 16 anaplastic oligodendrogliomas, WHO grade III; 14 anaplastic oligoastrocytomas, WHO grade III; and 6 glioblastomas with a major oligodendroglial component, WHO grade IV. The clinical files were reviewed. Three neuropathologists evaluated the histological slides independently. Loss-of-heterozygosity analysis for 1p and 19q was performed by PCR. Favorable prognostic factors from univariate analyses included seizures as presenting symptom, female sex, location in the frontal lobe, low WHO grade, classic histology, absence of gemistocytic cells, and combined 1p/19q loss. Solitary 19q loss was a negative prognostic marker. 1p/19q status was of prognostic significance in both tumors with classic and nonclassic oligodendroglial histology. In the multivariate analysis, WHO grade II (P< .001), frontal tumor location (P= .002), and combined 1p/19q loss (P< .001) remained favorable prognostic variables. Our results suggest that tumor location, WHO grade, and 1p/19q status are important independent variables associated with survival in oligodendroglial tumors. The study suggests that solitary 19q loss is a negative prognostic variable and that 1p/19q loss is associated with prolonged survival also in oligodendroglial tumors without classic histology.

Entities:  

Mesh:

Year:  2011        PMID: 21856683      PMCID: PMC3199152          DOI: 10.1093/neuonc/nor114

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  37 in total

1.  Can morphology predict 1p/19q loss in oligodendroglial tumours?

Authors:  D Scheie; M Cvancarova; S Mørk; K Skullerud; P A Andresen; I Benestad; E Helseth; T Meling; K Beiske
Journal:  Histopathology       Date:  2008-11       Impact factor: 5.087

2.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma.

Authors:  Robert B Jenkins; Hilary Blair; Karla V Ballman; Caterina Giannini; Robert M Arusell; Mark Law; Heather Flynn; Sandra Passe; Sara Felten; Paul D Brown; Edward G Shaw; Jan C Buckner
Journal:  Cancer Res       Date:  2006-10-15       Impact factor: 12.701

3.  Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

Authors:  Constance A Griffin; Peter Burger; Laura Morsberger; Raluca Yonescu; Sharon Swierczynski; Jon D Weingart; Kathleen M Murphy
Journal:  J Neuropathol Exp Neurol       Date:  2006-10       Impact factor: 3.685

4.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

Authors:  Martin J van den Bent; Antoine F Carpentier; Alba A Brandes; Marc Sanson; Martin J B Taphoorn; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; Laslo Sipos; Hanny Haaxma-Reiche; Johannes M Kros; Mathilde C M van Kouwenhoven; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

6.  Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.

Authors:  Luigi Mariani; Gianluca Deiana; Erik Vassella; Ali-Reza Fathi; Christine Murtin; Marlène Arnold; Istvan Vajtai; Joachim Weis; Peter Siegenthaler; Martina Schobesberger; Michael M Reinert
Journal:  J Clin Oncol       Date:  2006-09-11       Impact factor: 44.544

7.  Correlation among pathology, genotype, and patient outcomes in glioblastoma.

Authors:  Taku Homma; Takao Fukushima; Salvatore Vaccarella; Yasuhiro Yonekawa; Pier Luigi Di Patre; Silvia Franceschi; Hiroko Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2006-09       Impact factor: 3.685

8.  Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.

Authors:  C Ryan Miller; Christopher P Dunham; Bernd W Scheithauer; Arie Perry
Journal:  J Clin Oncol       Date:  2006-12-01       Impact factor: 44.544

9.  Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Caterina Giannini; Peter C Burger; Brian A Berkey; J Gregory Cairncross; Robert B Jenkins; Minesh Mehta; Walter J Curran; Ken Aldape
Journal:  Brain Pathol       Date:  2008-03-26       Impact factor: 6.508

10.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.

Authors:  François Ducray; Ahmed Idbaih; Aurélien de Reyniès; Ivan Bièche; Joëlle Thillet; Karima Mokhtari; Séverine Lair; Yannick Marie; Sophie Paris; Michel Vidaud; Khê Hoang-Xuan; Olivier Delattre; Jean-Yves Delattre; Marc Sanson
Journal:  Mol Cancer       Date:  2008-05-20       Impact factor: 27.401

View more
  15 in total

1.  Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.

Authors:  Sevin Turcan; Vladimir Makarov; Julian Taranda; Yuxiang Wang; Armida W M Fabius; Wei Wu; Yupeng Zheng; Nour El-Amine; Sara Haddock; Gouri Nanjangud; H Carl LeKaye; Cameron Brennan; Justin Cross; Jason T Huse; Neil L Kelleher; Pavel Osten; Craig B Thompson; Timothy A Chan
Journal:  Nat Genet       Date:  2017-11-27       Impact factor: 38.330

Review 2.  Seizures in oligodendroglial tumors.

Authors:  Melissa Kerkhof; Christa Benit; Alberto Duran-Pena; Charles J Vecht
Journal:  CNS Oncol       Date:  2015-10-19

3.  Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Authors:  Ross C Laxton; Sergey Popov; Lawrence Doey; Alexa Jury; Ranj Bhangoo; Richard Gullan; Chris Chandler; Lucy Brazil; Gill Sadler; Ron Beaney; Naomi Sibtain; Andrew King; Istvan Bodi; Chris Jones; Keyoumars Ashkan; Safa Al-Sarraj
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

4.  Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.

Authors:  Jiaxin Zhao; Wenjie Ma; Hong Zhao
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

5.  Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals.

Authors:  Yan-Xi Li; Abudumijiti Aibaidula; Zhifeng Shi; Hong Chen; Kay Ka-Wai Li; Nellie Yuk-Fei Chung; Ryan Rui Yang; Danny Tat-Ming Chan; Wai Sang Poon; Ka Lok Ryan Lee; Ying Mao; Jinsong Wu; Aden Ka-Yin Chan; Liangfu Zhou; Ho-Keung Ng
Journal:  J Neurooncol       Date:  2018-05-14       Impact factor: 4.130

6.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.

Authors:  Melike Pekmezci; Terri Rice; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Helen Hansen; Hugues Sicotte; Thomas M Kollmeyer; Lucie S McCoy; Gobinda Sarkar; Arie Perry; Caterina Giannini; Tarik Tihan; Mitchel S Berger; Joseph L Wiemels; Paige M Bracci; Jeanette E Eckel-Passow; Daniel H Lachance; Jennifer Clarke; Jennie W Taylor; Tracy Luks; John K Wiencke; Robert B Jenkins; Margaret R Wrensch
Journal:  Acta Neuropathol       Date:  2017-03-02       Impact factor: 15.887

7.  Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.

Authors:  Céline Duval; Marie de Tayrac; Karine Michaud; Florian Cabillic; Claudie Paquet; Peter Vincent Gould; Stéphan Saikali
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

8.  A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Authors:  Rebecca Senetta; Ludovica Verdun di Cantogno; Luigi Chiusa; Isabella Castellano; Patrizia Gugliotta; Anna Sapino; Paola Cassoni
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

9.  Anaplastic oligodendroglioma: advances and treatment options.

Authors:  Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.972

Review 10.  The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Authors:  Manish K Aghi; Brian V Nahed; Andrew E Sloan; Timothy C Ryken; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2015-11-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.